The headline figure, when you first encounter it, sounds wrong. By November 2025, a single weekly injection had become the highest selling pharmaceutical product in South Africa. According to IQVIA sales data confirmed by Aspen Pharmacare, Mounjaro had eclipsed every other medicine on the local market. Aspen's senior executive Stavros Nicolaou put the milestone publicly: it had become the largest pharmaceutical product in the country.
This was eleven months after launch. The medication had only been available locally for type 2 diabetes since December 2024. The weight management indication had only been added in October 2025. By the end of January 2026, Mounjaro held 52 percent of the SA GLP-1 market by value. Aspen forecast sales over R1.3 billion in the year through June 2026, with the CEO calling it "the quickest brand to reach" that scale.
How did a single medication, in one of the most competitive markets in healthcare, reach that position that quickly?
Four overlapping reasons explain it. None alone is sufficient. The combination is what produced the result.
One: The Clinical Results Were Better Than Anything That Came Before
The clearest reason is the simplest. Tirzepatide produces stronger trial outcomes than any previous weight management or type 2 diabetes medication. The SURPASS programme demonstrated HbA1c reductions of 2 to 2.4 percentage points across multiple comparators, including semaglutide. The SURMOUNT programme showed mean weight reduction of 20 percent at the maximum 15 mg dose. SURMOUNT-5 directly compared tirzepatide to semaglutide head to head, and tirzepatide came out ahead.
None of this was incremental progress. The previous generation of GLP-1 medications (liraglutide, dulaglutide, semaglutide) had produced steady improvements but nothing that fundamentally reshaped expectations. Tirzepatide did. Patients who had been managing weight without much success on older medications, sometimes for decades, saw substantial change. Specialists who had been cautious about pharmacotherapy for obesity reconsidered. Word travelled.
Two: Aspen Made It Available Fast And Wide
Eli Lilly had options when planning sub-Saharan African distribution of Mounjaro. The partnership with Aspen Pharmacare, signed in August 2023, turned out to be central to the speed of the SA rollout. Aspen is JSE listed, manufactures pharmaceuticals at scale across multiple South African sites, and has decades of relationships with SA pharmacies and prescribers. Within weeks of SAHPRA approval, Mounjaro was on pharmacy shelves nationwide.
Compare this to Wegovy, also a globally significant medication, launched in SA eight months after Mounjaro. The distribution scale, the prescriber familiarity, and the pharmacy stocking happened slower simply because Aspen was not running it. Mounjaro had a head start, and Aspen used it.
Aspen also handled the operational backbone in a way that turned out to matter. The KwikPen was registered locally. Pharmacy training rolled out alongside availability. Patient information materials were produced. The clinical scaffolding around the medication was built quickly enough that the medication became accessible practically as soon as it was technically available.
Three: The Indication Expansion Caught The Wave
Mounjaro launched in SA for type 2 diabetes in December 2024. This is the original SURPASS indication. It would have been a meaningful but not headline-making launch. Diabetes treatment is a competitive space with multiple existing options.
The October 2025 weight management approval changed the picture entirely. South Africa, like much of the world in 2025, was experiencing intense interest in GLP-1 medications for weight loss, partly driven by celebrity use of Ozempic off label, partly by genuine clinical demand, partly by the cultural shift toward viewing obesity as a treatable condition rather than a willpower failure.
Mounjaro arrived in this market with stronger trial data than the alternatives (Ozempic was off label and limited to 1 mg max dose in SA, Wegovy did not launch until August 2025) and immediate availability. People who had been waiting, sometimes for years, for an effective weight management medication had one.
If You Are Considering Mounjaro
An online consultation reviews your medical history and determines whether the medication is appropriate.
Start ConsultationFour: The Public Conversation Shifted
The cultural moment matters more than usual in this story. By 2024 and 2025, conversations about weight management medications had moved from medical journals to dinner tables. Celebrities discussed their use publicly. Major news organisations ran extensive feature coverage. Social media filled with both legitimate information and considerable misinformation about the medications.
In South Africa specifically, the conversation overlapped with a broader recognition of the local obesity burden. According to several public health reports, South Africa has among the highest obesity rates in sub-Saharan Africa, with significant downstream cardiovascular and metabolic disease consequences. The medical case for effective weight management treatment was being articulated more clearly than it had been in decades.
Mounjaro arrived into this conversation as the strongest available option. Even patients who had not previously considered medication for weight management started asking about it. Doctors who had not previously prescribed weight management medications started reading the trial data. The use case expanded faster than typical for a new medication.
What The Sales Numbers Actually Mean
The "biggest medicine in SA" headline is striking but worth unpacking. South Africa has a relatively small population (about 60 million) and a constrained pharmaceutical market by global standards. Becoming the biggest medicine here is meaningful but does not imply the scale of, for example, becoming the biggest medicine in the United States.
The R2.2 billion SA GLP-1 market that Mounjaro now leads is significant but compares to a global GLP-1 market measured in tens of billions of dollars. Mounjaro's 52 percent SA market share reflects strong dominance in a category that itself is growing rapidly. The category growth is part of the story. As more patients become aware of treatment options and more medical aids consider cover, the absolute size of the category continues to expand.
What the numbers do show, clearly, is that Mounjaro reached scale in SA faster than typical for a major new medication. Aspen's CEO described it as "the quickest brand to reach" R1.3 billion in sales. That speed is the noteworthy part. The size in absolute terms is smaller than global headlines might imply.
What This Means For Patients
For patients in SA considering Mounjaro, the market dominance has practical implications. Availability is generally good across the country. Pharmacist familiarity with the medication is widespread. Prescriber experience has accumulated. The medication is not a novel curiosity but an established treatment option.
It also means competition has shaped the picture. Novo Nordisk responded to Mounjaro's strength by cutting Wegovy prices in March 2026, with a second reduction submitted shortly after. The presence of two strong competitors at this scale benefits patients through pricing pressure that would not exist in a single-product market.
What Comes Next
Aspen has indicated plans to push Mounjaro registration across sub-Saharan Africa during 2026. CEO Stephen Saad told investors in early 2026 that the SA registration of the KwikPen gave the company a platform for regional expansion. If those registrations succeed, the SA experience will be repeated across multiple African markets.
Generic tirzepatide is years off, with key SA patents not expiring until the 2030s. This means Mounjaro will remain the only tirzepatide product in the SA market for the foreseeable future. The competitive pressure will come from other branded alternatives (Wegovy, plus future entrants like retatrutide if it reaches SA), not from generic copies.
The market position Mounjaro reached in 2025 is therefore likely to persist for several years. Patient and prescriber familiarity, distribution scale, and clinical track record compound. New entrants will face the same obstacles Mounjaro itself overcame.